Diseño, síntesis y evaluación biológica de nuevos derivados de piridazinoindol e indol como agonistas de los receptores MT1/MT2 de melatonina para el tratamiento de los trastornos del sueño

Since melatonin (MLT) was discovered, several physio-pathological functions have been associated with this hormone. One of the most important functions of this natural ligand is the regulation of sleep-wake cycles and its implication in insomnia and other sleep disorders. MLT exerts its actions thro...

Full description

Bibliographic Details
Main Authors: Castrillo, N. (Nerea), Aldana, I. (Ignacio), Galiano, S. (Silvia)
Format: info:eu-repo/semantics/doctoralThesis
Language:spa
Published: 2016
Subjects:
Online Access:https://hdl.handle.net/10171/39872
_version_ 1793400569537232896
author Castrillo, N. (Nerea)
Aldana, I. (Ignacio)
Galiano, S. (Silvia)
author_facet Castrillo, N. (Nerea)
Aldana, I. (Ignacio)
Galiano, S. (Silvia)
author_sort Castrillo, N. (Nerea)
collection DSpace
description Since melatonin (MLT) was discovered, several physio-pathological functions have been associated with this hormone. One of the most important functions of this natural ligand is the regulation of sleep-wake cycles and its implication in insomnia and other sleep disorders. MLT exerts its actions through two GPCRs receptors, MT1 and MT2, which have been suggested as key targets in this area. Currently, numerous researches have focused their research on new melatoninergic ligands. We have reported design, synthesis and characterization of novel pyridazino[4,5-b]indole (PI) and indole (In) derivatives. In addition, these compounds have been evaluated biologically to melatonin receptors. Based on PI and In biological results, we designed a new pharmacophore to synthesize future leader ligands with potent affinity and activity to melatoninergic receptors with the following characteristics: an indole ring as central core, methoxy group substituted in the 6 position of indole ring, six-atom length distance between methoxy group and the first nitrogen atom of the side chain and two-methylene linker over the indole ring and attached to different nitrogenous chains such as N-acetamide, N-methylurea, N-ethylurea and N-methylsulfonamide.
format info:eu-repo/semantics/doctoralThesis
id oai:dadun.unav.edu:10171-39872
institution Universidad de Navarra
language spa
publishDate 2016
record_format dspace
spelling oai:dadun.unav.edu:10171-398722020-03-03T13:47:07Z Diseño, síntesis y evaluación biológica de nuevos derivados de piridazinoindol e indol como agonistas de los receptores MT1/MT2 de melatonina para el tratamiento de los trastornos del sueño Castrillo, N. (Nerea) Aldana, I. (Ignacio) Galiano, S. (Silvia) Química orgánica Diseño, síntesis y estudio de nuevos fármacos Since melatonin (MLT) was discovered, several physio-pathological functions have been associated with this hormone. One of the most important functions of this natural ligand is the regulation of sleep-wake cycles and its implication in insomnia and other sleep disorders. MLT exerts its actions through two GPCRs receptors, MT1 and MT2, which have been suggested as key targets in this area. Currently, numerous researches have focused their research on new melatoninergic ligands. We have reported design, synthesis and characterization of novel pyridazino[4,5-b]indole (PI) and indole (In) derivatives. In addition, these compounds have been evaluated biologically to melatonin receptors. Based on PI and In biological results, we designed a new pharmacophore to synthesize future leader ligands with potent affinity and activity to melatoninergic receptors with the following characteristics: an indole ring as central core, methoxy group substituted in the 6 position of indole ring, six-atom length distance between methoxy group and the first nitrogen atom of the side chain and two-methylene linker over the indole ring and attached to different nitrogenous chains such as N-acetamide, N-methylurea, N-ethylurea and N-methylsulfonamide. 2016-02-04T12:22:12Z 2016-02-04T12:22:12Z 2016 2013-12-20 info:eu-repo/semantics/doctoralThesis https://hdl.handle.net/10171/39872 spa info:eu-repo/semantics/openAccess application/pdf
spellingShingle Química orgánica
Diseño, síntesis y estudio de nuevos fármacos
Castrillo, N. (Nerea)
Aldana, I. (Ignacio)
Galiano, S. (Silvia)
Diseño, síntesis y evaluación biológica de nuevos derivados de piridazinoindol e indol como agonistas de los receptores MT1/MT2 de melatonina para el tratamiento de los trastornos del sueño
title Diseño, síntesis y evaluación biológica de nuevos derivados de piridazinoindol e indol como agonistas de los receptores MT1/MT2 de melatonina para el tratamiento de los trastornos del sueño
title_full Diseño, síntesis y evaluación biológica de nuevos derivados de piridazinoindol e indol como agonistas de los receptores MT1/MT2 de melatonina para el tratamiento de los trastornos del sueño
title_fullStr Diseño, síntesis y evaluación biológica de nuevos derivados de piridazinoindol e indol como agonistas de los receptores MT1/MT2 de melatonina para el tratamiento de los trastornos del sueño
title_full_unstemmed Diseño, síntesis y evaluación biológica de nuevos derivados de piridazinoindol e indol como agonistas de los receptores MT1/MT2 de melatonina para el tratamiento de los trastornos del sueño
title_short Diseño, síntesis y evaluación biológica de nuevos derivados de piridazinoindol e indol como agonistas de los receptores MT1/MT2 de melatonina para el tratamiento de los trastornos del sueño
title_sort diseño, síntesis y evaluación biológica de nuevos derivados de piridazinoindol e indol como agonistas de los receptores mt1/mt2 de melatonina para el tratamiento de los trastornos del sueño
topic Química orgánica
Diseño, síntesis y estudio de nuevos fármacos
url https://hdl.handle.net/10171/39872
work_keys_str_mv AT castrillonnerea disenosintesisyevaluacionbiologicadenuevosderivadosdepiridazinoindoleindolcomoagonistasdelosreceptoresmt1mt2demelatoninaparaeltratamientodelostrastornosdelsueno
AT aldanaiignacio disenosintesisyevaluacionbiologicadenuevosderivadosdepiridazinoindoleindolcomoagonistasdelosreceptoresmt1mt2demelatoninaparaeltratamientodelostrastornosdelsueno
AT galianossilvia disenosintesisyevaluacionbiologicadenuevosderivadosdepiridazinoindoleindolcomoagonistasdelosreceptoresmt1mt2demelatoninaparaeltratamientodelostrastornosdelsueno